Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients
- 1 March 2007
- journal article
- research article
- Published by Elsevier in Clinical Microbiology & Infection
- Vol. 13 (3) , 264-268
- https://doi.org/10.1111/j.1469-0691.2006.01622.x
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Costs and Outcomes Among Hemodialysis-Dependent Patients With Methicillin-Resistant or Methicillin-SusceptibleStaphylococcus aureusBacteremiaInfection Control & Hospital Epidemiology, 2005
- Risk Factors and Costs Associated With Methicillin-Resistant Staphylococcus aureus Bloodstream InfectionsInfection Control & Hospital Epidemiology, 2004
- American Society of Diagnostic and Interventional Nephrology: Section Editor: Stephen Ash: Catheter Management Protocol for Catheter‐Related Bacteremia ProphylaxisSeminars in Dialysis, 2003
- A Prospective Multicenter Study of Staphylococcus aureus BacteremiaMedicine, 2003
- Use of aStaphylococcus aureusConjugate Vaccine in Patients Receiving HemodialysisNew England Journal of Medicine, 2002
- Vascular access use in Europe and the United States: Results from the DOPPSKidney International, 2002
- The Economic Impact of Methicillin-Resistant Staphylococcus aureus in Canadian HospitalsInfection Control & Hospital Epidemiology, 2001
- Methicillin-ResistantStaphylococcus aureusin the Community: A Hospital-Based StudyInfection Control & Hospital Epidemiology, 1999
- Nosocomial infections in medical intensive care units in the United StatesCritical Care Medicine, 1999
- Vascular access for hemodialysisKidney International, 1999